Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.39 |
| ▸ | CSF1R | P07333 | 8/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22187949 | 0.86 | TGFBR1 (0.43) | TGFBR1CSF1RFLT3GRM2PDGFRA | |
| SCHEMBL3947048 | 0.82 | TGFBR1 (0.53) | TGFBR1CSF1RFLT3S1PR4PDGFRA | |
| SCHEMBL22166027 | 0.81 | ADORA2A (0.41) | TGFBR1GRM2 | |
| SCHEMBL31277069 | 0.81 | ADORA2A (0.41) | TGFBR1GRM2 | |
| SCHEMBL22186851 | 0.80 | S1PR4 (0.51) | TGFBR1CSF1RS1PR4 | |
| SCHEMBL16028424 | 0.80 | SCN9A (0.43) | TGFBR1 | |
| SCHEMBL16028837 | 0.80 | TGFBR1 (0.43) | TGFBR1CSF1RFLT3S1PR4PDGFRA | |
| SCHEMBL30891513 | 0.80 | TGFBR1 (0.43) | TGFBR1CSF1RFLT3S1PR4PDGFRA | |
| SCHEMBL3944630 | 0.80 | TGFBR1 (0.39) | TGFBR1S1PR4 | |
| SCHEMBL22165778 | 0.80 | S1PR4 (0.36) | TGFBR1CSF1RS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3902796-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | Nexys Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113348167-A | (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer | 奈可萨斯医药有限公司 | 2021-09-03 | — | — | CN | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | TGFBR1 1/4885CSF1R 81/4885FLT3 361/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | TGFBR1 2/4885CSF1R 61/4885FLT3 644/4885 |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | TGFBR1, TGFBR2, ACVR1 | TGFBR1 1/4885CSF1R 81/4885FLT3 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.